Supernus Pharmaceuticals Inc SUPN:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
24.15quote price arrow down-0.97 (-3.86%)
Volume
1,112,674
52 week range
13.12 - 31.99

...

Loading . . .

KEY STATS

  • Open25.24
  • Day High25.63
  • Day Low23.98
  • Prev Close24.15
  • 52 Week High31.99
  • 52 Week High Date02/10/21
  • 52 Week Low13.12
  • 52 Week Low Date03/18/20
  • Market Cap1.277B
  • Shares Out52.87M
  • 10 Day Average Volume0.84M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • 1 Year % Change26.9

RATIOS/PROFITABILITY

  • EPS (TTM)2.41
  • P/E (TTM)10.02
  • Fwd P/E (NTM)19.12
  • EBITDA (MRQ)193.305M
  • ROE (MRQ)20.43%
  • Revenue (MRQ)477.29M
  • Gross Margin (MRQ)92.03%
  • Net Margin (MRQ)27.09%
  • Debt To Equity (MRQ)53.67%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Supernus Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive...
Charles Newhall III
Chairman
Jack Khattar
President
James Kelly
Chief Financial Officer
Address
9715 Key West Avenue
Rockville, MD
20850
United States